中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

QUARTERLY UPDATES ON THE IMPLEMENTATION OF ACTION PLANS TO RESOLVE THE DISCLAIMER OF OPINION

The board of directors (the "**Board**") of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") hereby provides the following quarterly updates on the implementation of the Group's action plans to improve the Group's liquidity and financial position and to resolve the disclaimer of opinion on going concern of the Company's auditor as set out in the annual report of the Company for the year ended 31 December 2025(the "**Annual Report**") (the "**Disclaimer of Opinion**"). Unless otherwise defined in this announcement, terms used herein shall have the same meanings as those used in the Annual Report.

As of the date of this announcement, the quarterly update on the implementation of the action plan to address the Disclaimer of Opinion is as follows:

CORE STRATEGIC TRANSFORMATION AND BUSINESS PROGRESS

On 25 March 2026, the Company completed the major transaction in relation to the acquisition of 100% of the issued shares of the target companies and the issue of consideration shares under specific mandate, and the target companies became indirect wholly-owned subsidiaries of the Company. Upon completion of the acquisition, the Company indirectly holds 58.11% equity interest in Zhejiang Kangyuan Medical Device Co., Ltd.* (浙江康源醫療器械有限公司) ("**Kangyuan**") through its wholly-owned subsidiaries. The completion of this acquisition marks an important milestone in the Group's transformation towards an artificial intelligence (AI) health management platform covering the full cycle of "testing–treatment–rehabilitation".

Kangyuan's core AI diagnostic products, such as the AI X-Ray Bone Density System and Portable AI X-Ray Device, along with its 12 patents and 25 sets of source codes, have been incorporated into the Group's product and technology portfolio, enriching the Group's product line and core competitiveness in the field of AI-powered bone health diagnostics and medical imaging technology, thereby expanding its AI health diagnostic and testing robotics business.

Following the completion of the acquisition, the Group has been actively promoting the integration of Kangyuan's operations, production systems, and sales channels to accelerate the commercialisation of AI diagnostic products. As at the date of this announcement, the Group has achieved small batch delivery of its Portable AI X-Ray Device to customers.

PROGRESS ON CAPITAL STRUCTURE IMPROVEMENT

In respect of the remaining debt restructuring, the Group continuously and actively negotiates with major creditors (including substantial shareholders and connected parties) on debt restructuring proposals to renew and extend the repayment period of existing borrowings or convert borrowings into shares, and seeks waivers from certain restrictive covenants in the relevant loan agreements. As at the date of this announcement, certain major lenders have indicated their willingness to explore and support in principle for the Group's restructuring proposal. The Group plans to submit a new restructuring proposal to the Board in due course under the relevant framework. As at the date of this announcement, no concrete or definitive agreement or memorandum of understanding has been entered into by the Group.

In respect of new financing and strategic investments, following the termination of the issuance of convertible bonds by the Company in February 2026, the Company has not ceased its efforts and continues to actively engage with investment institutions interested in the medical and health technology sector, and is exploring other structured financing options with existing shareholders and new potential strategic investors to introduce capital.

The Board will continue to take active measures to address the uncertainties relating to going concern that form the basis for the Disclaimer of Opinion, and will publish further announcements as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 30 April 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao and Mr. Ng Ming Kwan.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. The content of these statements is not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. The Company and its directors, officers, employees, agents, affiliates, advisers or representatives shall not assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information or to correct any inaccuracies in these statements.

* *For identification purposes only*